PHOSPHOAMINOPHOSPHONIC ACID-GUANYLATE ESTER
Structure-based development of new RAS-effector inhibitors from a combination of active and inactive RAS-binding compounds.
STEYKLVVVGADGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLC VFAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLV REIRKHKEKMSK
0.1 M, TrisCl, 0.2 M NaOAc and 30-35 % PEG 4000
Medical Research Council (United Kingdom)
HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS
TEYKLVVVGAGGVGKSALTIQLIQNHFVDEYDPTIEDSYRKQVVIDGETCLLDILDTAGQEEYSAMRDQYMRTGEGFLCV FAINNTKSFEDIHHYREQIKRVKDSEDVPMVLVGNKCDLPSRTVDTKQAQDLARSYGIPFIETSAKTRQGVDDAFYTLVR EIRKHKEKMSK